Galderma Group AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GALD.SW research report →
Price Chart
About the company
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology.
- CEO
- Flemming Ørnskov
- IPO
- 2024
- Employees
- 7,676
- HQ
- Zug, ZG, CH
Get TickerSpark's AI analysis on GALD.SW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $39.46B
- P/E
- 51.71
- Fwd P/E
- 34.50
- PEG
- 0.52
- P/S
- 8.43
- P/B
- 4.87
- EV/EBITDA
- 38.61
- Div Yield
- 0.21%
- Gross Margin
- 66.95%
- Op Margin
- 17.08%
- Net Margin
- 14.65%
- ROE
- 10.46%
- ROIC
- 8.01%
Latest fiscal year · YoY change
- Revenue
- $5.24B+7.2%
- Gross Profit
- $3.61B+6.2%
- Op Income
- $876.00M
- Net Income
- $642.16M+152.5%
- EPS
- $2.72+154.2%
- OCF Growth
- +142.8%
- FCF Growth
- +384.0%
- 52W High
- $188.25
- 52W Low
- $130.20
- 50D MA
- $175.02
- 200D MA
- $160.56
- Beta
- -0.10
- RSI (14)
- 42
- Avg Volume
- 434.69K
No earnings-call transcripts are available for GALD.SW yet.
- Free Float
- 41.3%
- Shares Outstanding
- 233.19M
- Float Shares
- 96.25M
Held by 1,103 ETFs
Biggest fund positions in GALD.SW by dollar value.
Our GALD.SW coverage
Recent articles, reports, and earnings notes.
Want a deeper read on GALD.SW?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
EQT exits Galderma Group AG in full via largest sponsor-backed block trade ever
prnewswire.com · Mar 13
EQT agrees to sale of shares in Galderma Group AG to L'Oréal S.A.
prnewswire.com · Dec 8
L’ORÉAL GROUPE TO REINFORCE ITS STRATEGIC INVESTMENT IN GALDERMA WITH AN ADDITIONAL 10% BRINGING ITS TOTAL PARTICIPATION TO 20%
globenewswire.com · Dec 8
LE GROUPE L’OREAL ANNONCE LE RENFORCEMENT DE SON INVESTISSEMENT STRATEGIQUE DANS GALDERMA EN PRENANT 10% SUPPLEMENTAIRES ET DETENIR AINSI 20% DU CAPITAL
globenewswire.com · Dec 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.